Limited time offer! 10% off your first blood test order!
Ten-marker panel combining core female fertility markers with full thyroid function for a complete reproductive hormonal assessment.
or 4 interest-free payments of £39.75 with Klarna
A ten-marker comprehensive fertility panel for women — combining AMH, FSH, LH, oestradiol, progesterone, prolactin.
Thyroid disorders are one of the most treatable and commonly overlooked causes of female infertility and miscarriage. The Comprehensive Female Fertility and Thyroid Panel recognises this by combining the seven core female fertility markers with full thyroid function in a single assessment.
Fertility markers: AMH (ovarian reserve), FSH and LH (pituitary drive), oestradiol (follicular environment), progesterone (ovulation confirmation), prolactin (anovulation screening), and testosterone (PCOS-related androgen excess and libido).
Thyroid: TSH, FT4, and FT3 — because TSH alone misses the pattern of poor T4-to-T3 conversion that can impair fertility and increase miscarriage risk, and because optimising thyroid function before conception has clear evidence for improving pregnancy outcomes.
NICE guidelines recommend TSH screening for women planning pregnancy and treating TSH above 2.5 mIU/L in women trying to conceive. This panel delivers the complete picture in a single, cycle-timed assessment. Venous draw required. GMC-physician reviewed results within 5 to 7 working days.
Understand what each marker measures, why it matters, and what the science says — not just a list of numbers.
Stable marker of remaining egg pool; reflects fertility timeline and ovarian response potential.
Pituitary follicle-stimulating hormone; elevated on days 2 to 5 suggests declining ovarian reserve.
Pituitary ovulation trigger; elevated LH-to-FSH ratio is a feature of PCOS.
Baseline oestradiol contextualises FSH; very high early oestradiol can falsely suppress FSH.
Day 21 marker confirming ovulation and luteal phase quality.
Elevated prolactin is a common, treatable cause of anovulation and infertility.
Screens for androgen excess from PCOS or adrenal pathology as a cause of anovulation.
Primary thyroid screen; TSH above 2.5 mIU/L in women trying to conceive warrants discussion with a GP.
Main thyroid secretory hormone; adds detail to TSH in borderline or symptomatic presentations.
Active thyroid hormone; poor T4-to-T3 conversion can impair fertility even when TSH appears normal.
This panel is designed for adults who want a comprehensive, evidence-based picture of their metabolic health — not a GP referral panel.
Women who have been trying to conceive for 6 or more months
Those with a history of miscarriage or recurrent pregnancy loss
Women with irregular cycles, PCOS symptoms, or unexplained anovulation
Those planning pregnancy in the next 12 months who want a comprehensive pre-conception baseline
The fertility markers in this panel require careful cycle-day timing: FSH, LH, oestradiol, prolactin, and AMH on days 2 to 5; progesterone on day 21. In women with irregular cycles, ovulation predictor kits are recommended to identify ovulation timing for the day 21 draw. AMH reflects egg quantity only — egg quality, which is the primary determinant of conception success after 35, cannot be assessed by a blood test. FT3 conversion is influenced by illness, nutritional status, and physiological stress, and should be interpreted alongside clinical context. This panel does not include thyroid antibodies (TPO Ab, TG Ab); if autoimmune thyroid disease is suspected, the Autoimmune Thyroid Screen should be added.
From order to physician-reviewed report in as little as three working days.
Three options designed to fit your schedule, location, and preference — all producing a laboratory-standard sample.
Adults 18+ in mainland UK. Not suitable if you have had a transfusion in the last 3 months.
Order anytime; kit dispatched within 24 hours Mon–Fri.
Allow 24–48 hours for sample transit on top of lab processing time.
Adults 18+ within 20 miles of a serviced city centre.
Mon–Sun, 06:00–20:00. Next-day booking typical.
Sample reaches the lab within 24 hours of collection.
Adults 16+ with photo ID. Paediatric draws by appointment at selected sites.
Mon–Fri, with Saturday hours at most metropolitan locations.
Samples processed same-day at the receiving clinic.
Every test is processed in a UKAS ISO 15189-accredited laboratory, overseen by GMC-registered physicians, and governed by UK GDPR. No overseas processing, no offshore data.
Follow these guidelines to ensure accurate, reproducible results. Most markers are sensitive to recent food, exercise, and sleep.
Can't find your answer? Our clinical support team is available Monday to Friday, 9am–5pm.
Contact supportTSH alone screens for overt thyroid dysfunction, but misses two important fertility-relevant scenarios. First, borderline TSH (2.0 to 4.0 mIU/L, technically ‘normal’) is now considered suboptimal for conception — NICE and fertility guidelines recommend TSH below 2.5 mIU/L when trying to conceive. Second, some women have normal TSH but impaired conversion of T4 to the active T3, producing peripheral thyroid insufficiency despite adequate TSH. Including FT4 and FT3 identifies this conversion problem and allows for more targeted support. Full thyroid function also provides the baseline data needed to safely monitor thyroid levels during pregnancy.
Most fertility and endocrine guidelines recommend a TSH below 2.5 mIU/L for women actively trying to conceive, and below 2.5 mIU/L in the first trimester once pregnant. This is lower than the standard adult upper reference range (typically 4.0 mIU/L) because thyroid demand increases significantly in early pregnancy, and starting from a higher TSH makes it more likely that hypothyroidism will develop in early pregnancy — a period critical for fetal brain development. If your TSH is between 2.5 and 4.0 mIU/L, your physician report will advise whether a GP conversation about levothyroxine is warranted in the context of your full thyroid picture.
PCOS causes irregular or absent ovulation (anovulation) — the most common cause of female infertility. This panel identifies the hormonal signature of PCOS through the LH-to-FSH ratio (elevated LH in PCOS), elevated testosterone (present in around 60% of PCOS cases), and the pattern of anovulation revealed by a low progesterone on day 21. A low progesterone (below 16 nmol/L) on day 21 suggests the cycle was anovulatory. AMH is often elevated in PCOS due to the large number of small antral follicles. The full picture allows the physician to comment on whether PCOS features are likely present and recommend appropriate next steps.
A progesterone below 16 nmol/L on day 21 suggests that ovulation may not have occurred in that cycle (anovulation) or that luteal phase support is inadequate (luteal phase deficiency). However, interpretation depends on when ovulation actually occurred. In a longer cycle (e.g. 35 days), ovulation may happen much later than day 14, and a day 21 test may simply be too early to capture the progesterone peak. If your cycles are irregular, ovulation predictor kits help identify the correct timing for a more interpretable mid-luteal progesterone. Your physician report will advise whether the pattern is concerning and what next steps are appropriate.
This panel includes thyroid function (TSH, FT4, FT3) but not thyroid antibodies (TPO Ab and TG Ab). Thyroid antibodies are relevant in the fertility context because elevated TPO antibodies — even with normal thyroid function — are associated with increased miscarriage risk and reduced IVF success rates. If you have a personal or family history of autoimmune thyroid disease, elevated TPO antibodies, or recurrent pregnancy loss, adding the Autoimmune Thyroid Screen to this assessment gives a more complete picture. Your physician report will advise if thyroid antibody testing is recommended based on your results and clinical context.
